Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
SSE:600613
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (18.5), the stock would be worth ¥6.16 (5% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 17.6 | ¥5.87 |
0%
|
| 3-Year Average | 18.5 | ¥6.16 |
+5%
|
| 5-Year Average | 21.3 | ¥7.08 |
+21%
|
| Industry Average | 30.7 | ¥10.21 |
+74%
|
| Country Average | 28.8 | ¥9.58 |
+63%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
SSE:600613
|
3.1B CNY | 17.6 | 50.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 140.4 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 35.3 | 27.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 24.8 | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.5 | 20.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 43.4 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 21.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 11.6 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
Glance View
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. engages in the research and development, manufacture, and sale of antitumor, cardiovascular, cold and cough, children medicine, and anti fungi drugs. The company is headquartered in Shanghai, Shanghai and currently employs 1,371 full-time employees. is a China-based company principally engaged in research and development, manufacture and sale of pharmaceuticals. The Company’s products are targeted for the treatment of influenza, cardio cerebrovascular diseases, rheumatoid bone diseases and in the areas of oncology, antifungal, antipyretic and gynaecology. The firm's main products include cantharidin sodium vitamin B6 injection, cantharidin sodium injection and other Chinese patent drug products. The firm distributes its products in domestic market.
